Clinical trials: Leucovorin
Peritoneal Cavity Cancer
Hyperthermic Intraperitoneal Oxaliplatin for Peritoneal Malignancies
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00625092
- Testing
- fluorouracil, leucovorin calcium, oxaliplatin
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Colorectal Cancer, Metastatic Cancer
Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs in different ways may kill more tumor cells.
- Conditions
- Colorectal Cancer, Metastatic Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00005944
- Testing
- chemotherapy, fluorouracil, leucovorin calcium
- Where
- 18 sites in Belgium, France
- Sponsor
- UNICANCER
Colorectal Cancer
DC-CIK Immunotherapy Plus Chemotherapy vs Chemotherapy Alone in the Adjuvant Treatment of Stage III Colorectal Cancer
Stage III colorectal cancer constitutes more than half of the colorectal patients, and the prognosis does not improve much recently although varies of adjuvant drugs have been tried.
- Trial name
- NCT02415699
- Testing
- Fluorouracil, Oxaliplatin, Leucovorin
- Volunteers
- 100 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Stage IV Colorectal Cancer
Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques
Open label Phase II study of FOLFIRI + Panitumumab using ultra-selection technology with next generation high sensitivity genotyping of patients with stage IV colorectal cancer refractory to irinotecan without any mutation on…
- Trial name
- ULTRA (NCT01704703)
- Testing
- panitumumab, FOLFIRI
- Where
- Spain
- Volunteers
- 72 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Gastroesophageal Junction (GEJ) Adenocarcinoma
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma
This study is to evaluate the effectiveness of treatment for esophagogastric junction carcinoma, total neoadjuvant therapy (TNT) including pembrolizumab and FLOT is conducted, aiming to choose between surgery or organ…
- Trial name
- NCT07018570
- Testing
- Pembrolizumab, Docetaxel, Oxaliplatin
- Where
- Japan
- Volunteers
- 26 people
- Sponsor
- National Cancer Center Hospital East
Colorectal Neoplasm, Colorectal Cancer
Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases
This is a multicentre, open-label, parallel-group, phase II-III, superiority study that randomises patients with isolated resectable colorectal peritoneal metastases in a 1:1 ratio to receive either perioperative systemic therapy…
- Conditions
- Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant, Colorectal Carcinoma
- Trial name
- CAIRO6 (NCT02758951)
- Testing
- Perioperative systemic therapy, Perioperative CAPOX-bevacizumab, Perioperative FOLFOX-bevacizumab
- Where
- 9 sites in Belgium, Netherlands
- Volunteers
- 358 people
- Sponsor
- Koen Rovers
Colorectal Neoplasms, Colorectal Cancer
Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases
This is an open-label, parallel-group, phase 2 randomized trial which randomizes patients with isolated resectable colorectal cancer peritoneal metastases to receive preoperative systematic therapy followed by CRS+HIPEC and…
- Conditions
- Colorectal Neoplasms, Colorectal Cancer, Colorectal Cancer Metastatic, Peritoneal Metastases
- Trial name
- NCT05353582
- Testing
- Preoperative systematic therapy, CRS+HIPEC, Postoperative chemotherapy
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Sun Yat-sen University
Colorectal Neoplasms, Peritoneal Neoplasms
Adjuvant HIPEC in High Risk Colon Cancer
This study aims to determine the oncological effectiveness of adjuvant HIPEC, using intraperitoneal oxaliplatin with concomitant i.v.
- Trial name
- COLOPEC (NCT02231086)
- Testing
- Adjuvant HIPEC (open/laparoscopic), Standard adjuvant systemic chemotherapy, Diagnostic laparoscopy
- Where
- 9 sites in Netherlands
- Volunteers
- 204 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Pancreatic Cancer
QUILT-3.080: NANT Pancreatic Cancer Vaccine
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous Standard of Care (SoC) chemotherapy.
- Trial name
- NCT03586869
- Testing
- Aldoxorubicin HCl, ALT-803, ETBX-011
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- ImmunityBio, Inc.
Recurrent Colon Cancer, Recurrent Rectal Cancer
Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Radiolabeled monoclonal antibodies can find tumor cells and either kill them or carry tumor-killing substances to them without harming normal cells.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Trial name
- NCT01205022
- Testing
- irinotecan hydrochloride, leucovorin calcium, fluorouracil
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- City of Hope Medical Center
Ovary Cancer
An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery
This study looks to enroll subjects with ovarian cancer who will be having standard of care surgery to remove ovarian cancer tumors.
- Trial name
- NCT03011320
- Testing
- EC1456, 99mTc-Etarfolatide
- Where
- 2 sites in United States, Canada
- Volunteers
- 3 people
- Sponsor
- Endocyte
Rectal Cancer, Rectosigmoid Cancer
mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer
Patients with locally advanced rectal or rectosigmoid cancer staged cT3 CRM-negative with MRI will receive 6 cycles of neoadjuvant treatment with mFOLFOX6 (Arm A) vs. mFOLFOX6 + aflibercept (Arm B) followed by surgery.
- Trial name
- NCT03043729
- Testing
- Oxaliplatin, 5-FU, Leucovorin
- Where
- Germany
- Volunteers
- 119 people
- Sponsor
- AIO-Studien-gGmbH
Anal Cancer, Carcinoma of the Appendix
Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00654160
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Mayo Clinic
Metastatic Colorectal Cancer
Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone
The purpose of this study is to evaluate the treatment effect of panitumumab plus FOLFIRI compared to FOLFIRI alone as second line therapy for metastatic colorectal cancer.
- Trial name
- NCT00339183
- Testing
- Panitumumab, FOLFIRI
- Volunteers
- 1,186 people
- Sponsor
- Amgen
Hepatocellular Carcinoma, Chemotherapy Effect
Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
The goal of this clinical trial is to compare HAIC concurrently with sequentially combined with targeted and immunotherapies in terms of efficacy and safety in patients with potentially resectable intermediate and advanced HCC…
- Conditions
- Hepatocellular Carcinoma, Chemotherapy Effect, Chemotherapeutic Toxicity
- Trial name
- HAIC (NCT06041477)
- Testing
- Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU, Concurrent Lenvatinib, Concurrent PD-1 antibody
- Where
- China
- Volunteers
- 540 people
- Sponsor
- Sun Yat-sen University
BCLC Stage C Hepatocellular Carcinoma, Chemotherapy Effect
Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC
This is a multi-center randomized phase III clinical study of first-line intravenous FOLFOX plus Camrelizumab and apatinib versus HAIC-FOLFOX plus Camrelizumab and apatinib for BCLC C stage hepatocellular carcinoma.
- Trial name
- NCT06172205
- Testing
- intravenous FOLFOX7 plus Camrelizumab and apatinib, HAIC-FOLFOX plus Camrelizumab and apatinib
- Where
- China
- Volunteers
- 262 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Pancreatic Adenocarcinoma
A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma
This is a phase II, single arm, non-randomized, open label study of liposomal irinotecan with FOLFOX in the neoadjuvant setting in patients with resectable or borderline resectable, previously untreated pancreatic adenocarcinoma.
- Trial name
- NCT03483038
- Testing
- Liposomal Irinotecan, FOLFOX regimen
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- University of Florida
Pancreatic Cancer
Combination Chemotherapy in Treating Patients With Advanced Cancer of the Pancreas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002955
- Testing
- fluorouracil, leucovorin calcium, trimetrexate glucuronate
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Southern California
Esophagus Adenocarcinoma
Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery
The present clinical trial is a prospective, investigator-initiated, single-arm, open-label, multicenter phase II trial investigating whether a definite organ preservation therapy consisting of the combination of durvalumab with…
- Trial name
- NCT05713838
- Testing
- Durvalumab, FLOT, mFOLFOX-6
- Where
- 22 sites in Germany
- Volunteers
- 32 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Colorectal Cancer Metastatic
Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal
To estimate progression-free-survival at 6 months in subjects treated in first-line with panitumumab and FOLFOX and with wild type RAS mCRC (metastatic colorectal cancer) confirmed in liquid biopsies before starting second line…
- Trial name
- BEYOND (NCT03751176)
- Testing
- Panitumumab, Irinotecan, Folinic acid
- Where
- 18 sites in Spain
- Volunteers
- 31 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.